Literature DB >> 26487581

Risk factors for neuroendocrine neoplasms: a systematic review and meta-analysis.

E Leoncini1, G Carioli2, C La Vecchia2, S Boccia1, G Rindi3.   

Abstract

BACKGROUND: Neuroendocrine neoplasms (NENs) are rare cancers mainly of lung and digestive tract. Little is known on risk factors. The aim of this work is to define the risk factors for NEN development by extensive review and meta-analysis of published data.
METHODS: The search was conducted on Medline, Scopus, and Web of Science following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. The Newcastle-Ottawa scale was used for study quality. Meta-analyses were conducted by primary site. Odds ratio (OR), hazard ratio, risk ratio, standardized incidence ratio, and associated 95% confidence intervals (CIs) were abstracted. Data were combined and analyses carried out for risk factors considered by at least two studies. Random-effects model was adopted for study variation.
RESULTS: Of 1535 extracted articles, 24 were enrolled. Meta-analyses were possible for pancreas, small intestine, and rectum. Risk for NEN associated with: (i) family history of cancer at all investigated sites (lung, stomach, pancreas, small intestine, appendix, and colon; OR 2.12 [95% CI 1.40-3.22, I(2) = 0.0%, P = 0.681] at meta-analysis in pancreas); (ii) body mass index (BMI) or diabetes (stomach, pancreas, and small intestine; OR of 2.76 [95% CI 1.65-4.64, I(2) = 58.5%, P = 0.090] for diabetes at meta-analysis in pancreas); (iii) cigarette smoking (lung, stomach, pancreas, and small intestine; OR of 1.34 [95% CI 1.10-1.63, I(2) = 0.0%, P = 0.780] and of 1.59 [95% CI 1.07-2.37, I(2) = 32.9%, P = 0.225] for smokers versus never-smokers at meta-analysis for pancreas and small intestine); (iv) alcohol consumption (pancreas and rectum; OR of 2.44 [95% CI 1.07-5.59, I(2) = 65.8%, P = 0.054] and of 1.53 [95% CI 0.99-2.35, I(2) = 0.0%, P = 0.630] for heavy drinkers versus never-drinkers at meta-analysis for pancreas and rectum).
CONCLUSIONS: Family history of cancer is the most relevant risk factor for NEN development at all investigated sites, followed by BMI and diabetes. Cigarette smoking and alcohol consumption are potential risk factors for selected anatomical sites.
© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  digestive tract; lung; neuroendocrine neoplasms; risk factors

Mesh:

Year:  2015        PMID: 26487581     DOI: 10.1093/annonc/mdv505

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  33 in total

1.  Prevalence of Small Intestine Carcinoid Tumors: A US Population-Based Study 2012-2017.

Authors:  Mohannad Abou Saleh; Emad Mansoor; Mohammad Anindo; Gerard Isenberg
Journal:  Dig Dis Sci       Date:  2018-12-05       Impact factor: 3.199

2.  Associations of Tobacco and Alcohol Use with Risk of Neuroendocrine Tumors of the Small Intestine in Utah.

Authors:  Karen Curtin; Lisa A Cannon-Albright; James VanDerslice; Zhe Yu; Kimberly A Herget; Ramya Thota; Deborah W Neklason
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-09-26       Impact factor: 4.254

Review 3.  Racial Disparity in Gastrointestinal Cancer Risk.

Authors:  Hassan Ashktorab; Sonia S Kupfer; Hassan Brim; John M Carethers
Journal:  Gastroenterology       Date:  2017-08-12       Impact factor: 22.682

Review 4.  Nutrition and neuroendocrine tumors: An update of the literature.

Authors:  Barbara Altieri; Luigi Barrea; Roberta Modica; Giovanna Muscogiuri; Silvia Savastano; Annamaria Colao; Antongiulio Faggiano
Journal:  Rev Endocr Metab Disord       Date:  2018-06       Impact factor: 6.514

5.  Risk of Primary Neuroendocrine Pancreatic Tumor After a First Primary Cancer: A US Population-Based Study.

Authors:  Geetanjali R Kamath; Michelle K Kim; Emanuela Taioli
Journal:  Pancreas       Date:  2019-02       Impact factor: 3.327

6.  Racial Disparity in Incidence and Survival for Gastrointestinal Stromal Tumors (GISTs): an Analysis of SEER Database.

Authors:  Mark B Ulanja; Mohit Rishi; Bryce D Beutler; Kenneth G Konam; Santhosh Ambika; Tomas Hinojosa; Francis T Djankpa; Wei Yang; Nageshwara Gullapalli
Journal:  J Racial Ethn Health Disparities       Date:  2019-06-18

Review 7.  Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine.

Authors:  Guido Rindi; Bertram Wiedenmann
Journal:  Nat Rev Endocrinol       Date:  2020-08-24       Impact factor: 43.330

8.  Specific Growth Rate as a Predictor of Survival in Pancreatic Neuroendocrine Tumors: A Multi-institutional Study from the United States Neuroendocrine Study Group.

Authors:  Jordan J Baechle; Paula Marincola Smith; Marcus Tan; Carmen C Solórzano; Alexandra G Lopez-Aguiar; Mary Dillhoff; Eliza W Beal; George Poultsides; Eleftherios Makris; Flavio G Rocha; Angelena Crown; Clifford Cho; Megan Beems; Emily R Winslow; Victoria R Rendell; Bradley A Krasnick; Ryan Fields; Shishir K Maithel; Christina E Bailey; Kamran Idrees
Journal:  Ann Surg Oncol       Date:  2020-04-23       Impact factor: 5.344

9.  Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case-control study.

Authors:  T Feola; G Puliani; F Sesti; R Modica; R Centello; R Minotta; G Cannavale; S Di Meglio; V Di Vito; R Lauretta; M Appetecchia; A Colao; A Lenzi; A M Isidori; A Faggiano; E Giannetta
Journal:  J Endocrinol Invest       Date:  2022-01-18       Impact factor: 4.256

10.  Implications of neuroendocrine tumor and diabetes mellitus on patient outcomes and care: a matched case-control study.

Authors:  Yael N Kusne; Heidi E Kosiorek; Matthew R Buras; Patricia M Verona; Kyle E Coppola; Kelley A Rone; Curtiss B Cook; Nina J Karlin
Journal:  Future Sci OA       Date:  2021-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.